Bravo Thompson, H.; Chattopadhyay, P.; Subhawong, T.; Palmer, M.-C.; Torralbas Fitz, S.; Crawford, B.; Rosenberg, A.; Temple, H.T.; Jonczak, E.
MRI-Based Delta Necrosis as a Prognostic Marker Following Neoadjuvant Chemotherapy in Soft Tissue Sarcoma. Cancers 2026, 18, 291.
https://doi.org/10.3390/cancers18020291
AMA Style
Bravo Thompson H, Chattopadhyay P, Subhawong T, Palmer M-C, Torralbas Fitz S, Crawford B, Rosenberg A, Temple HT, Jonczak E.
MRI-Based Delta Necrosis as a Prognostic Marker Following Neoadjuvant Chemotherapy in Soft Tissue Sarcoma. Cancers. 2026; 18(2):291.
https://doi.org/10.3390/cancers18020291
Chicago/Turabian Style
Bravo Thompson, Harold, Priya Chattopadhyay, Ty Subhawong, Malcolm-Christopher Palmer, Sergio Torralbas Fitz, Brooke Crawford, Andrew Rosenberg, H. Thomas Temple, and Emily Jonczak.
2026. "MRI-Based Delta Necrosis as a Prognostic Marker Following Neoadjuvant Chemotherapy in Soft Tissue Sarcoma" Cancers 18, no. 2: 291.
https://doi.org/10.3390/cancers18020291
APA Style
Bravo Thompson, H., Chattopadhyay, P., Subhawong, T., Palmer, M.-C., Torralbas Fitz, S., Crawford, B., Rosenberg, A., Temple, H. T., & Jonczak, E.
(2026). MRI-Based Delta Necrosis as a Prognostic Marker Following Neoadjuvant Chemotherapy in Soft Tissue Sarcoma. Cancers, 18(2), 291.
https://doi.org/10.3390/cancers18020291
